High cumulative doses of pegylated liposomal doxorubicin are not associated with cardiac toxicity in patients with gynecologic malignancies.
OBJECTIVE
The purpose of this study was to determine the cardiac safety of pegylated liposomal doxorubicin (PLD) in patients receiving high cumulative doses of PLD.


METHODS
A retrospective chart review of women with gynecologic malignancies treated at Roswell Park Cancer Institute from 2002 through 2007 who received cumulative doses of PLD >or=400 mg/m(2) was performed.


RESULTS
Forty-two of 116 patients met the inclusion criteria. The mean age at initiation of PLD therapy was 63 years. The mean cumulative dose of PLD was 663.9 mg/m(2) (range 400-1,524 mg/m(2)). The mean cumulative number of cycles of PLD given was 9.8 (range 5-25). Multigated acquisition (MUGA) scans were obtained in 93% (39/42) of patients prior to or immediately following their first dose of PLD. The mean baseline ejection fraction was 63% (range 49-76%). Follow-up MUGA scans were performed on 7 patients (17%). Two of these patients had a decrease in their ejection fraction, but of only 3 and 1%. The remaining 5 patients who had follow-up MUGA scans had an average increase in their left ventricular ejection fraction of 4% (range 1-9%). No patients developed clinical evidence of congestive heart failure while being treated with PLD. There were no treatment interruptions or discontinuations due to cardiac toxicity.


CONCLUSIONS
Cumulative doses of PLD >or=400 mg/m(2) are not associated with clinically evident cardiac toxicity in gynecologic oncology patients.
Kesterson
Joshua P
JP
Division of Gynecologic Oncology, Roswell Park Cancer Institute, Buffalo, NY 14263, USA.
Odunsi
Kunle
K
Lele
Shashikant
S
D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D004317:Doxorubicin / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D005833:Genital Neoplasms, Female / Q000188:drug therapy*; D006321:Heart / Q000187:drug effects*; D006801:Humans; D008875:Middle Aged; D011092:Polyethylene Glycols / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D012189:Retrospective Studies
D000903:Antibiotics, Antineoplastic; C506643:liposomal doxorubicin; D011092:Polyethylene Glycols; D004317:Doxorubicin
Ann Oncol. 2007 Apr;18(4):716-21
17301073
Gynecol Oncol. 2001 May;81(2):206-12
11330951
Ann Oncol. 2000 Aug;11(8):1029-33
11038041
Semin Oncol. 2006 Feb;33(1):2-14
16473642
J Clin Oncol. 2008 Aug 1;26(22):3777-84
18669466
Gynecol Oncol. 2005 Jan;96(1):10-8
15589573
J Clin Oncol. 1997 Mar;15(3):987-93
9060537
J Clin Oncol. 2001 Jul 15;19(14):3312-22
11454878
Cancer. 2003 Jun 1;97(11):2869-79
12767102
Chemotherapy. 1993 Nov-Dec;39(6):410-5
8222869
Gynecol Oncol. 2001 Aug;82(2):323-8
11531287
Am J Med. 1987 Jun;82(6):1109-18
3605130
Chemotherapy. 1994 May-Jun;40(3):188-94
8205937
Cancer. 2004 May 15;100(10):2052-63
15139046
Gynecol Oncol. 2004 Jul;94(1):147-51
15262133
J Clin Oncol. 2000 Sep;18(17):3093-100
10963637
Ann Oncol. 2004 Mar;15(3):440-9
14998846
Oncol Res. 2008;17(2):51-8
18543606
Drug Saf. 2001;24(12):903-20
11735647
World Health Organ Tech Rep Ser. 2000;894:i-xii, 1-253
11234459